Ron II - Aardvark Therapeutics VP CMC
| AARD Stock | 12.45 0.35 2.89% |
VP
Ron II is VP CMC of Aardvark Therapeutics Common
| Address | 4370 La Jolla Village Drive, San Diego, CA, United States, 92122 |
| Phone | 858 225 7696 |
| Web | https://aardvarktherapeutics.com |
Aardvark Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3081) % which means that it has lost $0.3081 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4806) %, meaning that it created substantial loss on money invested by shareholders. Aardvark Therapeutics' management efficiency ratios could be used to measure how well Aardvark Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 18, 2026, Return On Tangible Assets is expected to decline to -0.25. In addition to that, Return On Capital Employed is expected to decline to -0.3. At present, Aardvark Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 3.2 M, whereas Return On Tangible Assets are forecasted to decline to (0.25).Similar Executives
| Found 5 records | VP Age | ||
| Thuy PharmD | Pyxis Oncology | N/A | |
| Michael GarciaWebb | Foghorn Therapeutics | N/A | |
| Nathaniel JD | Enanta Pharmaceuticals | 72 | |
| Karin Hellsvik | Foghorn Therapeutics | N/A | |
| Alex Therien | Eupraxia Pharmaceuticals Common | N/A | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.31 |
Aardvark Therapeutics Leadership Team
Elected by the shareholders, the Aardvark Therapeutics' board of directors comprises two types of representatives: Aardvark Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aardvark. The board's role is to monitor Aardvark Therapeutics' management team and ensure that shareholders' interests are well served. Aardvark Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aardvark Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| TienLi MD, Secretary CEO | ||
| Bryan Jones, Chief Officer | ||
| Zhenhuan Zheng, Chief Officer | ||
| Tom Bicsak, Head Quality | ||
| Dvorit Samid, Executive Affairs | ||
| Terrie Kellmeyer, Senior Affairs | ||
| Ron II, VP CMC | ||
| Andreas MD, Head Medicine | ||
| Justin Stege, VP Strategy | ||
| Timothy Kieffer, Chief Officer | ||
| Nelson Sun, Chief Officer | ||
| Nelson MBA, Chief Officer | ||
| Christian JD, General Counsel | ||
| MPH MD, Chief Officer |
Aardvark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aardvark Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 137.65 M | ||||
| Shares Outstanding | 21.77 M | ||||
| Shares Owned By Insiders | 14.55 % | ||||
| Shares Owned By Institutions | 60.44 % | ||||
| Number Of Shares Shorted | 1.77 M | ||||
| Price To Book | 2.16 X | ||||
| EBITDA | (22.65 M) | ||||
| Net Income | (20.59 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aardvark Therapeutics is a strong investment it is important to analyze Aardvark Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aardvark Therapeutics' future performance. For an informed investment choice regarding Aardvark Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aardvark Therapeutics Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Will Pharmaceuticals sector continue expanding? Could Aardvark diversify its offerings? Factors like these will boost the valuation of Aardvark Therapeutics. If investors know Aardvark will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aardvark Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Aardvark Therapeutics requires distinguishing between market price and book value, where the latter reflects Aardvark's accounting equity. The concept of intrinsic value - what Aardvark Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aardvark Therapeutics' price substantially above or below its fundamental value.
Understanding that Aardvark Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aardvark Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aardvark Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.